Monograph

The ERS Monograph is the quarterly book series from the ERS.

Each Monograph covers a specific area of respiratory medicine, providing in-depth reviews that give clinicians at all levels a concise, comprehensive guide to symptoms, diagnosis and treatment.

Antibiotics and the Lung

European Respiratory Society Monograph, Vol. 28. 2004

ISBN: 978-1-904097-72-3

DOI: 10.1183/1025448x.erm2804

To serve its primary function of gas exchange, the lung is the organ with the largest epithelial surface area in continuous contact with the external environment. The upper and lower airways of humans are repeatedly exposed to airborne particles and microorganisms. Infectious respiratory disorders are therefore an important part of our daily activities as practising physicians. Furthermore, the management of these infectious diseases continues to evolve. Physicians are continuously confronted with new challenges in the cost-effective management of these infectious diseases. Antibiotic treatment is a key factor in the treatment schedules of these diseases. Optimal treatment would be an antibiotic regimen specifically suited for a specific patient, the type of infection and the infecting pathogen to assure an optimal therapeutic outcome. The present issue of the Monograph not only covers basic knowledge about treatment with antibiotics but also provides state of the art information about a variety of different classes of antibiotics.

Preface E.F.M. Wouters Eur Respir Mon; 2004: 28: a
Introduction E.F.M. Wouters Eur Respir Mon; 2004: 28: b
Interrelationship of pharmacokinetics/pharmacodynamics: antibiotic dosing for the future G.W. Amsden Eur Respir Mon; 2004: 28: 1–12
Intrapulmonary penetration of antimicrobials and implications in the treatment of lower respiratory tract infections M. Cazzola, G. D'Amato, M.G. Matera Eur Respir Mon; 2004: 28: 13–44
Interaction of antibacterial agents with host respiratory defences M.T. Labro Eur Respir Mon; 2004: 28: 45–63
b-Lactams and the lung S. Gatermann, T.T. Bauer Eur Respir Mon; 2004: 28: 64–77
Macrolides and lower respiratory tract infections J. Dorca, S. Padrones, F. Manresa Eur Respir Mon; 2004: 28: 78–93
Fluoroquinolones and lower respiratory tract infections A. Kuhnke, H. Lode Eur Respir Mon; 2004: 28: 94–112
Treatment of difficult Gram-positive infections R. Cosentini, P. Tarsia, M. Cazzola, F. Blasi Eur Respir Mon; 2004: 28: 113–130
The impact of antibiotic resistance in the management of lower respiratory tract infections G.C. Schito, A. Marchese Eur Respir Mon; 2004: 28: 131–145
Lower respiratory tract infections: when are antibiotics mandatory? L.A. Mandell Eur Respir Mon; 2004: 28: 146–164
Epidemiological impact of antibiotic use/misuse in the community T. Welte Eur Respir Mon; 2004: 28: 165–174
Antibiotics and new guidelines for the treatment of lower respiratory tract infections G. Di Maria, L. Spicuzza, R. Polosa Eur Respir Mon; 2004: 28: 175–188
Are antibiotics useful in acute exacerbations of chronic bronchitis? F. Blasi, L. Allegra Eur Respir Mon; 2004: 28: 189–197
Cost-effective antibiotic management of community acquired pneumonia M. Niederman Eur Respir Mon; 2004: 28: 198–210
Antibiotic treatment for nosocomial pneumonia A. de Roux, H. Lode, A. Torres Eur Respir Mon; 2004: 28: 211–228
Pharmacological interactions between antibiotics and other drugs in the treatment of lower respiratory tract infections A. Novelli, E. Mini, T. Mazzei Eur Respir Mon; 2004: 28: 229–254
Future antibiotics and current practices for treating respiratory tract infections D. Ben avid, G. Rahav, E. Rubinstein Eur Respir Mon; 2004: 28: 255–267